Data from EMA (European Medicines Agency) - Curated by Toby Galbraith - Last updated 10 October 2017

Indication(s)

Movymia is indicated in adults.

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated.

Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Hypogonadism

Epidemiology, pathophysiology, diagnosis/treatment guidelines, recent publication summaries and more.

Visit Hypogonadism

Prostate Cancer

How can you balance the harmful effects of treatment with control of prostate cancer growth in otherwise healthy patients?

+ 1 more

Visit Prostate Cancer

Related Content

More information

Category Value
Agency product number EMEA/H/C/004368
Orphan designation No
Date First Approved 11-01-2017
Type Medicinal product subject to medical prescription
Marketing authorisation holder STADA Arzneimittel AG